STOCK TITAN

[Form 4] Arteris, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4

Paul L. Alpern, Vice President and General Counsel of Arteris, Inc. (AIP), reported transactions dated 10/01/2025 executed under a 10b5-1 trading plan adopted on June 5, 2025. The reporting person acquired 5,000 shares (transaction code M) at an effective price of $0.56 and sold 5,000 shares (transaction code S) at a weighted average price of $10.3089, with sale prices ranging from $10.16 to $10.51. After the transactions, the report shows 73,587 shares beneficially owned as to the non-derivative holdings and 85,000 shares when including derivative securities. The derivative shown is an option with a $0.56 exercise price exercisable beginning 10/01/2025 and expiring 10/23/2029. The filing is signed and dated 10/03/2025.

Paul L. Alpern, vicepresidente e responsabile legale di Arteris, Inc. (AIP), ha riportato transazioni datate 10/01/2025 eseguite ai sensi di un piano di negoziazione 10b5-1 adottato il 5 giugno 2025. Il soggetto indicante la segnalazione acquistato 5.000 azioni (codice di transazione M) a un prezzo effettivo di $0.56 e venduto 5.000 azioni (codice di transazione S) a un prezzo medio ponderato di $10.3089, con prezzi di vendita che variano da $10.16 a $10.51. Dopo le transazioni, la segnalazione mostra 73,587 azioni possedute beneficiariamente per le partecipazioni non derivate e 85,000 azioni includendo strumenti derivati. Il derivato indicato è un'opzione con prezzo di esercizio di $0.56 eseguibile a partire dal 10/01/2025 e scadenza il 10/23/2029. Il fascicolo è firmato e datato 10/03/2025.

Paul L. Alpern, Vicepresidente y Consejero General de Arteris, Inc. (AIP), reportó operaciones con fecha 10/01/2025 ejecutadas bajo un plan de negociación 10b5-1 adoptado el 5 de junio de 2025. La persona reportante adquirió 5,000 acciones (código de transacción M) a un precio efectivo de $0.56 y vendió 5,000 acciones (código de transacción S) a un precio ponderado de $10.3089, con precios de venta que oscilan entre $10.16 y $10.51. Después de las transacciones, el informe muestra 73,587 acciones de titularidad beneficiosa para las participaciones no derivadas y 85,000 acciones al incluir valores derivados. El derivado mostrado es una opción con un precio de ejercicio de $0.56 ejercitable a partir del 10/01/2025 y con vencimiento el 10/23/2029. El archivo está firmado y fechado el 10/03/2025.

Paul L. Alpern, Arteris, Inc. (AIP)의 부사장 겸 최고법무책임자로서 10/01/2025에 날짜가 기록된 거래를 10b5-1 거래계획에 따라 2025년 6월 5일에 채택하였고 실행했습니다. 신고대상자는 5,000주를 인수(거래코드 M)하여 실효가격 $0.56로 매수하고, 5,000주를 매도(거래코드 S)하여 가중평균가 $10.3089로 체결했으며, 매도가격은 $10.16에서 $10.51 사이였습니다. 거래 후 보고서에는 비파생보유지분으로 73,587주, 파생증권을 포함하면 85,000주가 보유로 표시됩니다. 보유 파생은 $0.56의 행사가격을 가진 옵션으로 10/01/2025에 행사 가능하고 10/23/2029에 만료됩니다. filing은 2025년 10월 3일에 서명 및 날짜가 기재되어 있습니다.

Paul L. Alpern, Vice-président et conseiller juridique général de Arteris, Inc. (AIP), a rapporté des opérations datées du 10/01/2025 exécutées dans le cadre d’un plan de négociation 10b5-1 adopté le 5 juin 2025. La personne déclarante a acquis 5 000 actions (code de transaction M) à un prix effectif de $0.56 et a vendu 5 000 actions (code de transaction S) à un prix moyen pondéré de $10.3089, les prix de vente allant de $10.16 à $10.51. Après les transactions, le rapport montre 73 587 actions détenues bénéfiCIAirement sur les participations non dérivées et 85 000 actions lorsqu’on inclut les dérivés. Le dérivé présenté est une option avec un prix d’exercice de $0.56 exploitable à partir du 10/01/2025 et arrivant à échéance le 10/23/2029. Le dépôt est signé et daté du 10/03/2025.

Paul L. Alpern, Vice President und General Counsel von Arteris, Inc. (AIP), berichtete Transaktionen mit Datum 10/01/2025, die unter einen 10b5-1-Handelsplan aufgenommen am 5. Juni 2025 durchgeführt wurden. Die meldende Person kaufte 5.000 Aktien (Transaktionscode M) zu einem effektiven Preis von $0.56 und verkaufte 5.000 Aktien (Transaktionscode S) zu einem gewogenen Durchschnittspreis von $10.3089, wobei die Verkaufspreise von $10.16 bis $10.51 reichten. Nach den Transaktionen zeigt der Bericht 73,587 Aktien, die als nicht ableitbare Beteiligungen gehalten werden, und 85,000 Aktien, wenn man Derivate einbezieht. Das gezeigte Derivat ist eine Option mit einem Ausübungspreis von $0.56, die ab dem 10/01/2025 ausübbar ist und am 10/23/2029 verfällt. Die Einreichung ist unterschrieben und datiert auf 10/03/2025.

Paul L. Alpern، نائب الرئيس والمستشار العام لشركة Arteris, Inc. (AIP)، أبلغ عن معاملات بتاريخ 10/01/2025 نفذت بموجب خطة تداول 10b5-1 اعتمدت في 5 يونيو 2025. قامت جهة الإبلاغ بشراء 5,000 أسهم (رمز المعاملة M) بسعر فعال قدره $0.56 و ببيع 5,000 أسهم (رمز المعاملة S) بسعر متوسط مرجح قدره $10.3089، وكانت أسعار البيع تتراوح بين $10.16 و$10.51. بعد المعاملات، يظهر التقرير 73,587 سهماً مملوكة بشكل مفيد فيما يتعلق بالحيازات غير المشتقة و 85,000 سهماً عند تضمين الأوراق المشتقة. المشتق المبيّن هو خيار بسعر تمارين $0.56 قابل للتنفيذ بدءاً من 10/01/2025 ويفسخ في 10/23/2029. تم توقيع الملف وتاريخه 10/03/2025.

Paul L. AlpernArteris, Inc. (AIP) 的副总裁兼法务长报告了日期为 10/01/2025 的在 10b5-1 交易计划下执行的交易,该计划于 2025年6月5日 通过。报告人 买入了5,000 股(交易代码 M)的实际价格为 $0.56,并且 卖出5,000 股(交易代码 S)的加权平均价格为 $10.3089,卖出价格范围为 $10.16$10.51。交易完成后,报告显示非衍生品持有的权益为 73,587 股,若包括衍生证券,总共为 85,000 股。所示衍生工具为执行价格为 $0.56 的期权,自 10/01/2025 起可行使,至 10/23/2029 到期。该备案于 2025年10月3日 签署并注明日期。

Positive
  • Transaction executed under a 10b5-1 plan adopted on June 5, 2025, indicating pre-established trading instructions
  • Sale price disclosed as a weighted average of $10.3089 with a reported per-trade range of $10.16–$10.51, providing transparency on execution
  • Derivative option remains outstanding with exercisable date 10/01/2025 and expiration 10/23/2029, and 85,000 shares total beneficially owned including derivatives
Negative
  • Non-derivative holdings decreased by 5,000 shares to 73,587 following the sale
  • Multiple sales occurred (prices ranged across $10.16–$10.51), which may complicate simple interpretation of proceeds without per-trade breakdown

Insights

TL;DR: Insider exercised and immediately sold 5,000 shares under a pre-established 10b5-1 plan.

The report shows a concurrent exercise (or deemed acquisition) of 5,000 shares at $0.56 and a sale of 5,000 shares at a weighted average of $10.3089. The seller discloses the sale price range ($10.16–$10.51), which indicates the sale occurred in multiple transactions.

This was executed under a disclosed 10b5-1 trading plan adopted on June 5, 2025, which documents pre-clearance and timing rules reducing the likelihood of impermissible insider trading claims.

TL;DR: Insider holdings remain material but were modestly reduced after the trade.

Non-derivative beneficial ownership following the reported transactions is 73,587 shares; including derivative securities the filing lists 85,000 shares beneficially owned. The filing also discloses a vesting schedule for the derivative shares that began vesting on August 26, 2020 with monthly vesting thereafter.

Filing is signed and dated 10/03/2025, providing an auditable record of the insider's activity as required under Section 16.

Paul L. Alpern, vicepresidente e responsabile legale di Arteris, Inc. (AIP), ha riportato transazioni datate 10/01/2025 eseguite ai sensi di un piano di negoziazione 10b5-1 adottato il 5 giugno 2025. Il soggetto indicante la segnalazione acquistato 5.000 azioni (codice di transazione M) a un prezzo effettivo di $0.56 e venduto 5.000 azioni (codice di transazione S) a un prezzo medio ponderato di $10.3089, con prezzi di vendita che variano da $10.16 a $10.51. Dopo le transazioni, la segnalazione mostra 73,587 azioni possedute beneficiariamente per le partecipazioni non derivate e 85,000 azioni includendo strumenti derivati. Il derivato indicato è un'opzione con prezzo di esercizio di $0.56 eseguibile a partire dal 10/01/2025 e scadenza il 10/23/2029. Il fascicolo è firmato e datato 10/03/2025.

Paul L. Alpern, Vicepresidente y Consejero General de Arteris, Inc. (AIP), reportó operaciones con fecha 10/01/2025 ejecutadas bajo un plan de negociación 10b5-1 adoptado el 5 de junio de 2025. La persona reportante adquirió 5,000 acciones (código de transacción M) a un precio efectivo de $0.56 y vendió 5,000 acciones (código de transacción S) a un precio ponderado de $10.3089, con precios de venta que oscilan entre $10.16 y $10.51. Después de las transacciones, el informe muestra 73,587 acciones de titularidad beneficiosa para las participaciones no derivadas y 85,000 acciones al incluir valores derivados. El derivado mostrado es una opción con un precio de ejercicio de $0.56 ejercitable a partir del 10/01/2025 y con vencimiento el 10/23/2029. El archivo está firmado y fechado el 10/03/2025.

Paul L. Alpern, Arteris, Inc. (AIP)의 부사장 겸 최고법무책임자로서 10/01/2025에 날짜가 기록된 거래를 10b5-1 거래계획에 따라 2025년 6월 5일에 채택하였고 실행했습니다. 신고대상자는 5,000주를 인수(거래코드 M)하여 실효가격 $0.56로 매수하고, 5,000주를 매도(거래코드 S)하여 가중평균가 $10.3089로 체결했으며, 매도가격은 $10.16에서 $10.51 사이였습니다. 거래 후 보고서에는 비파생보유지분으로 73,587주, 파생증권을 포함하면 85,000주가 보유로 표시됩니다. 보유 파생은 $0.56의 행사가격을 가진 옵션으로 10/01/2025에 행사 가능하고 10/23/2029에 만료됩니다. filing은 2025년 10월 3일에 서명 및 날짜가 기재되어 있습니다.

Paul L. Alpern, Vice-président et conseiller juridique général de Arteris, Inc. (AIP), a rapporté des opérations datées du 10/01/2025 exécutées dans le cadre d’un plan de négociation 10b5-1 adopté le 5 juin 2025. La personne déclarante a acquis 5 000 actions (code de transaction M) à un prix effectif de $0.56 et a vendu 5 000 actions (code de transaction S) à un prix moyen pondéré de $10.3089, les prix de vente allant de $10.16 à $10.51. Après les transactions, le rapport montre 73 587 actions détenues bénéfiCIAirement sur les participations non dérivées et 85 000 actions lorsqu’on inclut les dérivés. Le dérivé présenté est une option avec un prix d’exercice de $0.56 exploitable à partir du 10/01/2025 et arrivant à échéance le 10/23/2029. Le dépôt est signé et daté du 10/03/2025.

Paul L. Alpern, Vice President und General Counsel von Arteris, Inc. (AIP), berichtete Transaktionen mit Datum 10/01/2025, die unter einen 10b5-1-Handelsplan aufgenommen am 5. Juni 2025 durchgeführt wurden. Die meldende Person kaufte 5.000 Aktien (Transaktionscode M) zu einem effektiven Preis von $0.56 und verkaufte 5.000 Aktien (Transaktionscode S) zu einem gewogenen Durchschnittspreis von $10.3089, wobei die Verkaufspreise von $10.16 bis $10.51 reichten. Nach den Transaktionen zeigt der Bericht 73,587 Aktien, die als nicht ableitbare Beteiligungen gehalten werden, und 85,000 Aktien, wenn man Derivate einbezieht. Das gezeigte Derivat ist eine Option mit einem Ausübungspreis von $0.56, die ab dem 10/01/2025 ausübbar ist und am 10/23/2029 verfällt. Die Einreichung ist unterschrieben und datiert auf 10/03/2025.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Alpern Paul L

(Last) (First) (Middle)
C/O ARTERIS, INC.
900 E. HAMILTON AVE., SUITE 300

(Street)
CAMPBELL CA 95008

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Arteris, Inc. [ AIP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
VP and General Counsel
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/01/2025 M(1) 5,000 A $0.56 78,587 D
Common Stock 10/01/2025 S(1) 5,000 D $10.3089(2) 73,587 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Common Stock $0.56 10/01/2025 M 5,000 (3) 10/23/2029 Common Stock 5,000 $0.00 85,000 D
Explanation of Responses:
1. Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on June 5, 2025.
2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.16 to $10.51 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. 25% of the total shares vested on August 26, 2020; thereafter, 1/48th of the total shares vested monthly for 3 years, beginning on September 26,2020.
Remarks:
/s/ Paul Alpern 10/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Arteris insider Paul L. Alpern report on Form 4 (AIP)?

The filing reports that Paul L. Alpern acquired 5,000 shares at $0.56 and sold 5,000 shares at a weighted average price of $10.3089 on 10/01/2025 under a 10b5-1 plan.

When was the 10b5-1 trading plan adopted for the transactions?

The Form 4 states the 10b5-1 plan was adopted on June 5, 2025.

How many shares does Paul L. Alpern beneficially own after these transactions?

The filing shows 73,587 shares beneficially owned for non-derivative securities and 85,000 shares when including derivative securities.

What price range were the sold shares executed at?

The shares sold were executed at prices ranging from $10.16 to $10.51, with a reported weighted average of $10.3089.

Are there any outstanding options or derivatives disclosed?

Yes. The filing discloses a derivative with an exercise price of $0.56, exercisable 10/01/2025 and expiring 10/23/2029, underlying 5,000 shares.
Arteris, Inc.

NASDAQ:AIP

AIP Rankings

AIP Latest News

AIP Latest SEC Filings

AIP Stock Data

552.32M
29.79M
30.11%
47.91%
3.85%
Semiconductors
Semiconductors & Related Devices
Link
United States
CAMPBELL